The Truth About How Effective Sublocade for Addiction Is

Understanding how Sublocade works for addiction

If you are wondering how effective Sublocade is for addiction, you are not alone. Many people considering medication assisted treatment (MAT) want to know whether a monthly buprenorphine injection can really help them stay off opioids, how safe it is, and whether Medicaid will pay for it.

Sublocade is an extended release form of buprenorphine. It is given as a subcutaneous shot once a month and slowly releases medication to control withdrawal and cravings throughout the month. It is FDA approved to treat moderate to severe opioid use disorder and is meant to be used together with counseling and psychosocial support [1].

If you want a deeper dive into how the injection itself works in your body, you can explore more in detail at how does sublocade shot work. Here, you will focus on how well it actually works in real life, how it compares to other medications, and how Medicaid coverage fits in.

What Sublocade is and how it compares to other buprenorphine options

Sublocade contains buprenorphine, the same medication that is used in many daily oral products like Suboxone or Subutex. The key difference is how it is delivered and how long it lasts.

With products like Suboxone, you take buprenorphine under the tongue or inside the cheek every day. Sublocade replaces that daily dosing with a monthly injection that forms a small depot under your skin and then steadily releases buprenorphine for about a month [2].

You can learn more about how Sublocade stacks up against common daily options at sublocade vs suboxone comparison and can sublocade replace suboxone therapy. If you are still learning the basics of buprenorphine itself, subutex vs buprenorphine explained and buprenorphine vs methadone treatment can give helpful background.

The core point is that Sublocade gives you the same type of medication used in other buprenorphine programs, but in a long acting injection instead of a pill or film you take every day. That delivery method is a big part of why Sublocade can be so effective for some people.

What the research says about how effective Sublocade is

When you ask, “how effective is Sublocade for addiction,” you are really asking two related questions:

1. How well does it help you stay in treatment and stay off opioids
2. How does it compare with other medications like oral buprenorphine or methadone

Large 2025 analysis of buprenorphine treatments

One of the strongest sources of information is a large systematic review and network meta analysis that looked at 98 studies of opioid use disorder medications up through March 2025. This analysis included oral buprenorphine, methadone, various long acting injections, buprenorphine implants, and monthly extended release buprenorphine, also called BUP XR, which is the medication in Sublocade [3].

Key findings from that study include:

• Monthly injectable buprenorphine (Sublocade) had the highest probability of keeping people in treatment compared with all the other options that were studied
• It also had the highest probability of helping people achieve opioid abstinence
• Compared with oral buprenorphine, the injection significantly lowered the risk of illicit opioid use, with a rate ratio of 1.99, and compared with methadone, the rate ratio was 2.66, which means a better chance of staying off opioids while on treatment [3]
• Discontinuation rates were similar between most medications, but people on oral buprenorphine may have been somewhat more likely to stop treatment compared with those on the monthly injection, which points to better adherence with Sublocade [3]

The same analysis found that safety outcomes, including serious adverse events, vomiting, headache, insomnia, and other side effects, were broadly similar across medications. In other words, Sublocade did not appear to introduce new or unusual risks compared with other agonist treatments like methadone or oral buprenorphine [3].

The researchers also looked at health related quality of life. People on the monthly injection tended to report better recovery outcomes on a standardized measure called the Substance Use Recovery Evaluator compared with those on other long acting buprenorphine products or transmucosal (oral) buprenorphine [3]. That suggests the treatment can support not only abstinence, but also broader improvements in your daily life.

Individual clinical trial results

Earlier clinical trials give more detail about how people do over time with Sublocade. One 6 month phase 3 trial looked at people with moderate to severe opioid use disorder who were stabilized on transmucosal buprenorphine and then randomized to different Sublocade doses or placebo. From weeks 5 to 24:

• About 24 percent of those on the 300 mg dose and 21 percent of those on the 100 mg dose achieved opioid abstinence
• Only about 2 percent of those on placebo achieved abstinence
• Discontinuation rates were roughly similar between the two active Sublocade doses (about 36 to 38 percent) and lower than the placebo group (about 66 percent), which indicates that many more people stayed engaged in treatment when they received active medication [4]

Other research summarized by American Addiction Centers has shown that people treated with Sublocade have more days of abstinence from opioids than those who receive placebo injections, again pointing to meaningful real world benefit in terms of staying off opioids [5].

Rapid induction and early retention

A more recent multicenter trial published in 2025 explored a rapid induction protocol that might be closer to what you would experience in a modern clinic. Instead of requiring at least seven days of daily buprenorphine before the first shot, people received a single 4 mg dose of oral buprenorphine and then a same day Sublocade injection.

In this trial:

• Rapid induction was well tolerated
• People in the rapid induction group were more likely to still be in treatment at the time of their second injection compared with those on the standard, slower induction protocol
• The benefits were especially clear for people who tested positive for fentanyl at baseline, which is important given how common fentanyl is in the current drug supply
• A second injection given one week after the first was also well tolerated and had a similar safety profile in both induction groups [6]

For you, this suggests that Sublocade can be started more quickly than in the past without sacrificing safety, and that this rapid start may help you stay engaged in treatment during those vulnerable early weeks.

How Sublocade helps with cravings and withdrawal

The core of Sublocade’s effectiveness is how it manages cravings and withdrawal in a steady, predictable way. As an extended release buprenorphine formulation, it:

• Reduces opioid cravings
• Reduces withdrawal symptoms
• Blocks or blunts the effect of other opioids if you use them, which can make relapse less rewarding and easier to step away from [7]

Daily oral buprenorphine does the same thing in principle. The difference is consistency. Missed doses, taking medication irregularly, or intentionally skipping on days when you feel “okay” can all weaken protection. A long acting injection removes that day to day decision and keeps therapeutic levels of buprenorphine in your system between visits [5].

Many people find that this stability helps them focus more on counseling, rebuilding their lives, and addressing mental health and social stressors, instead of constantly thinking about medication timing and withdrawal risk.

If you prefer frequent dose adjustments or immediate symptom relief, a weekly injectable like Brixadi may sometimes be preferred, but if you value on going monthly coverage, Sublocade’s monthly schedule can be a better fit [8].

Safety, side effects, and real world risks

When you consider any medication, safety is as important as effectiveness. Overall, research suggests that Sublocade has a safety profile that is similar to other opioid agonist treatments.

Across randomized trials and observational studies:

• Serious adverse events have been uncommon
• Discontinuations because of side effects have been relatively low
• Common side effects have included injection site pain, itching, or nodules, constipation, nausea or vomiting, headache, fatigue, elevated liver enzymes, and insomnia [9]

The 2025 network meta analysis also found that rates of adverse events were generally comparable between monthly injectable buprenorphine and other agonist therapies like oral buprenorphine and methadone, indicating that the injection itself does not add major new safety concerns [3].

However, Sublocade does come with a boxed warning against intravenous use, because injecting the depot material into a vein could cause serious harm or death. For this reason, it must be given only by a health care professional in a clinical setting [10].

You can explore these issues in more detail at sublocade side effects and safety. Your own risk profile will depend on your medical history, other medications, and liver function, so it is important to talk through these factors with a prescriber.

Why long acting injections can improve adherence

One of the most consistent findings about Sublocade is that it improves adherence by removing the need to remember a daily pill or film. For many people with opioid use disorder, life is complicated by unstable housing, transportation problems, chaotic schedules, and intense triggers and stress. All of these can interfere with daily dosing.

With a monthly injection:

• You only need to attend a clinic visit roughly every 26 to 28 days
• Steady buprenorphine levels are maintained between visits
• There is no extra pill burden on busy or trigger filled days
• The risk of medication diversion or loss is reduced, since you do not keep a buprenorphine supply at home [11]

A 2018 assessment by the Institute for Clinical and Economic Review (ICER) characterized Sublocade as particularly appropriate for people who have unstable home situations, who struggle to commit to daily transmucosal therapy, or who are at high risk for diversion. The panel recommended that insurers could reasonably require that you first be stabilized on daily buprenorphine at doses of 24 mg or less for at least seven days before switching, although newer rapid induction research may eventually influence these policies [4].

The ICER panel did judge Sublocade’s price at that time as a relatively low value for money within the U.S. system, largely because of high list prices relative to other options [4]. That is one reason Medicaid coverage details matter so much when you are deciding whether this treatment is realistic for you.

Medicaid coverage and your out of pocket costs

If you have Medicaid, the key question is often not just “how effective is Sublocade for addiction,” but “can I realistically access it without being overwhelmed by cost.”

Many state Medicaid programs list Sublocade as a preferred drug. When that is the case, people generally pay low or no copay for the medication itself, as long as they meet any prior authorization criteria set by the plan [10]. Those criteria often include:

• A confirmed diagnosis of moderate to severe opioid use disorder
• Prior stabilization on a transmucosal buprenorphine product, though newer rapid induction protocols may eventually change how that is applied in practice
• Participation in a comprehensive treatment plan that includes counseling or psychosocial support [12]

To get a clearer picture of your personal situation, you can look at:

• is sublocade covered by medicaid
• medicaid coverage for sublocade injections
• cost of sublocade treatment with medicaid

These resources can help you understand how prior authorization, copays, and clinic billing usually work, and what you can expect to pay out of pocket.

If you are open to other buprenorphine formats, buprenorphine treatment covered by medicaid and buprenorphine clinic covered by medicaid can give you a broader look at daily or weekly options that Medicaid also supports.

If Sublocade is a preferred drug in your state Medicaid plan, your main barrier is often not the medication price itself but finding a clinic and prescriber that accept your coverage and are familiar with this injectable form of buprenorphine.

Finding a Sublocade provider who accepts Medicaid

Once you know that your plan covers Sublocade, the next step is to find a clinic that:

1. Is comfortable using long acting buprenorphine injections, and
2. Accepts your Medicaid plan for both visits and medication administration

You can start with:

• find sublocade clinic near me to locate programs that regularly administer this injection
• sublocade doctors that take medicaid to narrow the list to prescribers who already work with Medicaid

When you call clinics, it can help to ask specific questions:

• Do you offer Sublocade or other monthly buprenorphine injections
• Do you accept my specific Medicaid plan
• How do you handle prior authorizations
• Do you offer counseling on site, or do you coordinate with outside therapists

Good programs will also emphasize that Sublocade is part of a broader plan. The medication can reduce withdrawal and cravings and make relapse less likely, but combining MAT with counseling, peer support, and practical help with housing, work, or legal issues is what gives you the strongest foundation for long term recovery [13].

Weighing whether Sublocade is right for you

Sublocade is not automatically better for everyone, but it can be a strong option if you:

• Have moderate to severe opioid use disorder
• Struggle with daily adherence to medication
• Face a high risk of diversion or loss of take home buprenorphine
• Prefer fewer clinic visits and value consistent medication levels
• Are covered by Medicaid or another plan that makes the cost manageable

On the other hand, if you prefer close dose adjustments, worry about injections, or want more direct control over your day to day dose, a daily or weekly buprenorphine product may feel more comfortable. A thoughtful discussion with a prescriber who understands both Sublocade and other MAT options will help you match the treatment format to your life.

If you decide to move forward, sublocade injection for opioid treatment can help you understand the step by step process of induction, early follow up, and long term maintenance.

When you look at the total body of evidence, the answer to “how effective is Sublocade for addiction” is clear: for many people, especially those who struggle with adherence to daily medications, monthly injectable buprenorphine significantly improves treatment retention, reduces illicit opioid use, and supports better recovery outcomes, all with a safety profile similar to other standard MAT options [14]. The final decision is personal, but you have solid data and growing real world experience to guide your choice.

References

1. (Drugs.com, American Addiction Centers)
2. (Drugs.com, Brightside Clinic)
3. (PMC)
4. (PMC)
5. (American Addiction Centers)
6. (Indivior)
7. (American Addiction Centers, Brightside Clinic)
8. (Brightside Clinic)
9. (PMC, Indivior)
10. (Drugs.com)
11. (American Addiction Centers, Brightside Clinic, Drugs.com)
12. (Drugs.com, Indivior)
13. (American Addiction Centers, Indivior)
14. (PMC, American Addiction Centers, Drugs.com)